Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.19.3
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended 24 Months Ended 57 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2019
Dec. 31, 2018
Disaggregation of Revenue [Line Items]              
Prior period performance obligation revenue recognized     $ 25,800,000 $ 23,400,000      
Overpayment reimbursement liability $ 25,500,000   25,500,000   $ 25,500,000 $ 25,500,000 $ 35,900,000
Revenue recognized   $ 5,800,000   14,300,000 0    
Total revenues 228,772,000 249,815,000 677,592,000 768,412,000      
Contract liability 34,200,000   34,200,000   34,200,000 34,200,000 $ 91,100,000
Rayaldee              
Disaggregation of Revenue [Line Items]              
Revenue recognized 7,400,000   18,800,000        
Total revenues 19,661,000   47,241,000        
Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues 21,472,000 21,609,000 58,961,000 56,463,000      
Pfizer | Products              
Disaggregation of Revenue [Line Items]              
Revenue recognized           0  
Contract liability 28,000,000.0   28,000,000.0   $ 28,000,000.0 $ 28,000,000.0  
Pfizer | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues $ 19,500,000 $ 18,900,000 $ 55,100,000 $ 49,900,000